KR100440493B1 - Healthy drink comprising Alismatis Rhizoma extract and process for prepatration therof - Google Patents
Healthy drink comprising Alismatis Rhizoma extract and process for prepatration therof Download PDFInfo
- Publication number
- KR100440493B1 KR100440493B1 KR10-2000-0078052A KR20000078052A KR100440493B1 KR 100440493 B1 KR100440493 B1 KR 100440493B1 KR 20000078052 A KR20000078052 A KR 20000078052A KR 100440493 B1 KR100440493 B1 KR 100440493B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- taxa
- cells
- cell
- extracts
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 102
- 238000000034 method Methods 0.000 title claims abstract description 10
- 230000008569 process Effects 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 17
- 235000013361 beverage Nutrition 0.000 claims abstract description 14
- 239000012676 herbal extract Substances 0.000 claims abstract description 11
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 9
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 8
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 8
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 7
- 240000008866 Ziziphus nummularia Species 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 235000015197 apple juice Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 235000020687 goji berry extract Nutrition 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 230000000845 anti-microbial effect Effects 0.000 abstract description 17
- 230000003078 antioxidant effect Effects 0.000 abstract description 16
- 230000005965 immune activity Effects 0.000 abstract description 7
- 235000003599 food sweetener Nutrition 0.000 abstract description 5
- 239000003765 sweetening agent Substances 0.000 abstract description 5
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 4
- 239000012141 concentrate Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- -1 acidulant Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 210000004988 splenocyte Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 241000411851 herbal medicine Species 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 150000002978 peroxides Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 230000009696 proliferative response Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000009422 growth inhibiting effect Effects 0.000 description 5
- 239000000401 methanolic extract Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000029305 taxis Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000209514 Alismataceae Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241001333951 Escherichia coli O157 Species 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- 241000607598 Vibrio Species 0.000 description 3
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 3
- 241001247821 Ziziphus Species 0.000 description 3
- 244000126002 Ziziphus vulgaris Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- NULAJYZBOLVQPQ-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1 NULAJYZBOLVQPQ-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000736075 Schisandra Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- HNOSJVWYGXOFRP-UNPOXIGHSA-N (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](O)C(C)(C)O)C)CC[C@@]21C HNOSJVWYGXOFRP-UNPOXIGHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 235000013291 Alisma plantago aquatica Nutrition 0.000 description 1
- 240000004615 Alisma plantago-aquatica Species 0.000 description 1
- HNOSJVWYGXOFRP-UHFFFAOYSA-N Alisol A Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(O)C(C)(C)O)C)CCC21C HNOSJVWYGXOFRP-UHFFFAOYSA-N 0.000 description 1
- GBJKHDVRXAVITG-UNPOXIGHSA-N Alisol B Chemical compound O([C@@H]1[C@@H](O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C GBJKHDVRXAVITG-UNPOXIGHSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DORJGGFFCMZTHW-KXVAGGRESA-N C[C@H](C[C@H](O)[C@H]1OC1(C)C)C1=C2C[C@H](O)[C@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@]3(C)[C@@]2(C)CC1=O Chemical compound C[C@H](C[C@H](O)[C@H]1OC1(C)C)C1=C2C[C@H](O)[C@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@]3(C)[C@@]2(C)CC1=O DORJGGFFCMZTHW-KXVAGGRESA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- HCPSZQRUACPWRI-UHFFFAOYSA-N Linusic acid Chemical compound CCC(O)C(O)CC(O)C(O)CC(O)C(O)CCCCCCCC(O)=O HCPSZQRUACPWRI-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- QMCLOHXDDPMAMI-UHFFFAOYSA-N alisol B Natural products CC(C)C(=O)C(O)CC(C)C1=C2CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC1 QMCLOHXDDPMAMI-UHFFFAOYSA-N 0.000 description 1
- DORJGGFFCMZTHW-UHFFFAOYSA-N alisol C Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC(=O)C=1C(C)CC(O)C1OC1(C)C DORJGGFFCMZTHW-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000003516 cell number determination Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/51—Concentration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Abstract
본 발명은 택사건강음료 및 그 제조방법에 관한 것으로 항균활성, 항산화 효과 및 면역활성이 뛰어난 택사 추출물과 대추, 구기자 및 오미자 등의 생약재 추출물에 사과농축액, 산미제, 감미제 및 향료를 첨가하여 기능성이 증진된 택사건강음료를 제공하는 뛰어난 효과가 있다.The present invention relates to a taxa health beverage and a method for manufacturing the same, and adds apple concentrate, acidulant, sweetener and flavor to the extracts of herbal extracts such as taxa extract, jujube, wolfberry and Schisandra chinensis with excellent antimicrobial, antioxidant and immune activity. There is an excellent effect of providing enhanced tax health drinks.
Description
본 발명은 택사건강음료 및 그 제조방법에 관한 것이다. 더욱 상세하게는, 본 발명은 항균활성, 항산화 효과 및 면역활성이 뛰어난 택사추출물에 생약재 추출물 및 부재료를 혼합하여 제조함으로써 기능성이 증진된 택사건강음료 및 그 제조방법에 관한 것이다.The present invention relates to a taxi health drink and a manufacturing method thereof. More specifically, the present invention relates to a tactile health beverage with improved functionality by manufacturing a mixture of herbal medicine extracts and subsidiary ingredients in a medicinal extract extract having excellent antimicrobial activity, antioxidant effect and immune activity, and a method for producing the same.
택사과(澤瀉科;Alismataceae)식물인 택사(Alismatis Rhizoma)는 단자엽 식물중 진화하는 과정에서 분화된 잔존군으로 세계적으로 약 13속 90여종이 분포되어 있는데, 중국의 복건, 강서 사천, 귀천 및 운남지방에서도 많이 생산되고 있으며, 우리나라의 경우에는 그 생산량의 50% 이상을 차지하고 있는 전남 순천 지방을 비롯하여 전남 무안, 구례 및 경북 상주 지역에서 생산되고 있으며, 생약으로 쓰이는 택사는 질경이 택사(Alisma plantago-aquatica L. var. orientaleSamuels)가 주로 재배 생산된다. 택사의 함유성분은 전분 25%, 단백질 7%, 정유의 furfural, resin, 무기염과 triterpenoid계의 alisol A, B, C와 그 아세테이트(acetate) 및 당류로 알려져 있다. 이와 같은 택사는 예로부터 수분을 제거하고 오장을 도우며 기력을 튼튼히 하는 약재로 알려져 있으며, 칼륨(K) 많이 함유되어 있어 택사를 복용하게되면 뇨중의 칼륨(K)의 배출이 현저히 증가된다. 또한 택사는 혈중 콜레스테롤을 감소시키고, 혈압 및 혈중의 당을 낮추는 작용이 있고 사염화 탄소로 유발된 간독성에 유효한 보간작용이 있음이 보고된 바 있다. 또한 최근에는 택사분말이 무좀에도포약으로 쓰이고 있어 택사에는 다양한 생리활성물질이 존재하는 것으로 생각된다. 그러나 택사의 생리활성에 대한 실제적인 연구결과는 매우 부족하며 이를 이용한 건강식품에 대한 개발도 미흡한 실정이다. Alismatis Rhizoma , an Alismataceae plant, is a remnant group differentiated during the evolution of monocotyledonous plants, with about 13 genera and 90 species distributed worldwide. Fujian, Jiangxi, Sichuan, Guitian and It is also produced in Yunnan province, and in Korea, it is produced in the Jeonnam Suncheon region, which accounts for more than 50% of its production, in Muan, Gurye, and Sangju, Gyeongsangbuk-do, and the taxa used as a herbal medicine is Alisma plantago- aquatica L. var. orientale Samuels) is mainly grown and produced. The constituents of taxa are known as 25% starch, 7% protein, furfural, resin, essential salts, alisol A, B, C, and acetates and acetates of triterpenoids. Such taxa is known as a medicine that removes moisture, helps the intestine, and strengthens energy. It is contained a lot of potassium (K), and when the taxi is taken, potassium (K) in the urine is significantly increased. Taxa has also been reported to reduce blood cholesterol, lower blood pressure and blood sugar, and have an effective interpolation effect on hepatotoxicity induced by carbon tetrachloride. In addition, recently, the tactile powder has been used as a medicine for athlete's foot, so it is thought that various physiologically active substances are present in the tactical taxi. However, the actual research results on physiological activity of taxis are very insufficient and the development of health foods using them is insufficient.
본 발명자들은 상기와 같은 점을 착안하여 순천지역에서 생산되는 택사의 항균, 항산화 활성 및 면역반응 조절작용에 미치는 영향 등과 같은 생리활성을 규명하고 택사를 음료로 제조함으로써 본 발명을 완성하였다.The present inventors have completed the present invention by identifying the physiological activity such as the effects on the antibacterial, antioxidant activity and immune response control action of taxis produced in the Suncheon area by focusing on the above points and preparing the taxis as a beverage.
따라서, 본 발명의 목적은 택사건강음료의 제조방법을 제공하는 것이다. 본 발명의 다른 목적은 택사건강음료를 제공하는 것이다.Accordingly, it is an object of the present invention to provide a method for producing a tax health drink. Another object of the present invention is to provide a taxi health drink.
도 1은 본 발명의 바람직한 제조방법의 실시예를 공정별로 도시한 개략도이다.1 is a schematic diagram showing an embodiment of a preferred manufacturing method of the present invention for each process.
도 2은 본 발명 택사추출물의 항균활성 측정을위해 시험균주에 택사 물추출물을 첨가한후 생성된 생육저해환을 나타내는 평판배지의 사진도이다.Figure 2 is a photograph of a plate medium showing the growth inhibition ring produced after the addition of the tax water extract to the test strain to determine the antimicrobial activity of the tax extract of the present invention.
도 3a는 본 발명 택사추출물의 바실러스 서브틸러스(B. subtilis)균주의 성장 억제효과를 나타낸 그래프이다.Figure 3a is a graph showing the growth inhibitory effect of the Bacillus subtilis strain of the present invention tack extract.
도 3b는 본 발명 택사추출물의 슈도모나스 아에리그노사(Pseudomonas aerignosa) 균주의 성장 억제효과를 나타낸 그래프이다.Figure 3b is a graph showing the growth inhibitory effect of Pseudomonas aerignosa strain of the present taxa extract.
도 3c는 본 발명 택사추출물의 대장균(E.coli) 균주의 성장 억제효과를 나타낸 그래프이다.Figure 3c is a graph showing the growth inhibitory effect of E. coli strains of the present invention tack extract.
도 3d는 본 발명 택사추출물의 살모넬라 티피무리움(Salmonella typhymuriu- Figure 3d is Salmonella typhymuriu of the present invention taxa extract ( Salmonella typhymuriu-
m)균주의 성장 억제 효과를 나타낸 그래프이다. m ) It is a graph showing the growth inhibitory effect of the strain.
도 3e는 본 발명 택사추출물의 비브리오 파라하모리티커스(Vibrio parahaemo liticus) 균주의 성장 억제효과를 나타낸 그래프이다.Figure 3e is a graph showing the growth inhibitory effect of the Vibrio parahaemo liticus strain of the present taxa extract.
도 4은 택사추출물 처리에 따른 살모넬라 티피무리움(Salmonella typhymuriu Figure 4 is Salmonella typhymuriu according to the process of extracting the taxa ( Salmonella typhymuriu
m)의 전자현미경 사진도이다. m ) electron micrograph.
도 5는 50℃에서 7일 동안 리놀레산 자동산화 과정중 택사추출물(100㎕) 첨가에 따른 과산화물가의 변화를 나타낸 그래프이다.Figure 5 is a graph showing the change in peroxide value according to the addition of the tack extract (100 μl) during linoleic acid automatic oxidation for 7 days at 50 ℃.
도 6는 50℃에서 7일 동안 리놀레산의 자동산화 과정중 택사추출물을 농도별 첨가에 따른 과산화물가의 변화를 나타낸 그래프이다.Figure 6 is a graph showing the change in peroxide value according to the concentration of the tax extract during the automatic oxidation of linoleic acid for 7 days at 50 ℃.
도 7은 본 발명 택사추출물을 쥐간에 처리시 TBA가의 변화를 나타낸 그래프이다.Figure 7 is a graph showing the change in TBA value when the present invention is treated with a rat extract.
도 8a는 본 발명 택사추출물을 비장세포에 처리시 비장세포의 증식에 미치는 영향을 나타낸 그래프이다.Figure 8a is a graph showing the effect on the proliferation of splenocytes when the present invention is treated to splenocytes.
도 8b는 본 발명 택사추출물을 B세포에 처리시 B세포의 증식에 미치는 영향을 나타낸 그래프이다.Figure 8b is a graph showing the effect on the proliferation of B cells when the present invention is treated to B cell tack extract.
도 9a는 본 발명 택사추출물이 동종항원에 대해 반응하는 T세포 증식에 미치는 영향을 나타낸 그래프이다.Figure 9a is a graph showing the effect of the present invention tack extract on T cell proliferation in response to homologous antigen.
도 9b는 본 발명 택사추출물이 동종항원에 대해 반응하는 T세포의 저해도를 나타낸 그래프이다.Figure 9b is a graph showing the degree of inhibition of T cells in response to the tax extract of the present invention homologous antigen.
도 10는 본 발명 택사추출물이 동종항원에 대해 반응하는 T세포의 세포독성에 미치는 영향을 나타낸 그래프이다.Figure 10 is a graph showing the effect of the present invention taxa extract on the cytotoxicity of T cells in response to homologous antigen.
도 11은 본 발명에 의한 택사건강음료 제품의 사진도이다.Figure 11 is a photographic view of the tactile health beverage product according to the present invention.
본 발명의 상기 목적은 택사 추출물을 제조하여 식중독 및 병원성 미생물에 대한 항균활성, 리놀레산과 간지질에 대한 항산화 효과 및 면역활성을 확인한 뒤 택사추출물, 생약재 추출물 및 기타 부원료를 사용하여 기능성이 증진된 택사건강음료를 제조함으로써 달성하였다.The object of the present invention is to prepare a tack extract to check the antibacterial activity against food poisoning and pathogenic microorganisms, the antioxidant effect and immune activity against linoleic acid and hepatic lipids, and then the tack extract enhanced functionality using the tack extract, herbal extracts and other side ingredients Achieved by preparing a health beverage.
이하, 본 발명의 구성을 설명한다.Hereinafter, the configuration of the present invention will be described.
본 발명은 택사의 항균, 항산화 및 면역활성을 조사하기 위하여 메탄올, 에탄올 및 물을 사용하여 택사 추출물을 제조하는 단계; 상기 택사추출물의 항균 활성을 조사하기 위하여 식중독 및 병원성 미생물에 대한 항균활성을 측정하고, 택사추출물의 처리에 따른 미생물의 형태변화를 조사하는 단계; 택사추출물의 항산화효과를 조사하기 위하여 리놀레산에 대한in vitro항산화 효과 및 간 지질과산화 억제 기능에 대하여 조사하는 단계; 택사 추출물의 면역세포 증식효과, 대식세포주의 일산화질소 생산에 미치는 영향, 동종항원에 대한 증식반응, 동종항원에 의한 T세포 사이토카인 분비량의 억제 및 동종항원에 대한 T세포의 살세포 작용 억제효과를 조사하는 단계; 택사와 생약재에 각각 10배의 물을 가수하여 80℃에서 2회에 거쳐 5시간동안 추출, 농축하여 택사추출물과 생약추출물을 제조하는 단계; 택사추출물과 생약추출물 및 부원료인 사과과즙, 산미제, 감미제, 및 향료를 선정된 최적 배합 비율에 따라 칭량하고 혼합하는 단계; 상기 단계의 시료에 가향하고 정용한 뒤 1㎛ 막여과 필터로 여과하는 단계; 여과액을 93℃에서 15초간 순간 살균한후 용기에 충전하는 단계; 충전된 시료를 80℃에서 20분간 살균한 후 제품화하는 단계로 구성된다.이때 상기 정용하는 단계는, 각각의 재료들의 혼합량을 “정해진 용량에 맞추는”것을 의미하며, 상기 칭량 및 혼합되는 각각의 재료들을 소정의 배합비율에 따라 혼합량이 정확히 조절된다.또한 상기 저당은 공지의 전분과 물엿의 중간적인 기능적 특성을 가진 당으로, 1당(글루코사민), 2당, 3당 등 분자량이 작고 가수분해율이 20정도이며, 전분을 효소에 의해 부분적으로 가수분해하고 정제, 농축한 것이다. 저당은 부형성이 우수하고 갈변에 대한 저항성을 보유하고 있어 식품가공 분야에 널리 사용되는 공지의 식품소재이며, 예컨대 유아용 식품, 소프트 비스켓, 스넥류, 껌류, 젤리류의 젤 형성제, 빙과류의 빙점 조정, 커피프리머, 식품의 증량제 등에 사용된다. 또한 예컨대 딸기에는 포도당을 비롯해 저당 또는 과당 등이 다량 함유되어 있으며, 말산, 구연산, 타르타르산 등이 딸기의 새콤달콤한 맛을 제공하는 것이다.The present invention comprises the steps of preparing a taxi extract using methanol, ethanol and water to investigate the antibacterial, antioxidant and immune activity of the taxi; Measuring antimicrobial activity against food poisoning and pathogenic microorganisms to investigate the antimicrobial activity of the taxa extract, and examining the morphological changes of the microorganisms according to the treatment of the taxa extract; Irradiating with respect to the in vitro antioxidant activity and lipid peroxidation inhibiting liver functions for the linoleic acid in order to examine the antioxidant activity of the extract Alismataceae; Effects of Taxa Extract on Immune Cell Proliferation, Effects of Macrophage Cells on Nitric Oxide Production, Proliferative Response to Homologous Antigens, Inhibition of T Cell Cytokine Secretion by Homologous Antigens, and T Cell Killer Action on Homologous Antigens Investigating; Preparing water and medicinal extracts by extracting and concentrating water for 10 times with water twice as much as 10 times in taxa and herbal medicines at 80 ° C. for 5 hours; Weighing and mixing the tactile extract, the herbal extract, and the subsidiary apple juice, acidulant, sweetener, and flavoring according to the selected optimal blending ratio; Flavoring and applying to the sample of the step and filtering with a 1 μm membrane filtration filter; Sterilizing the filtrate at 93 ° C. for 15 seconds and then filling the vessel; The filled sample is sterilized at 80 ° C. for 20 minutes and then commercialized. The step of applying the above means that the mixing amount of the respective materials is “fit to a predetermined capacity”, and the weighing and mixing of each material The amount of mixed sugar is precisely controlled according to a predetermined blending ratio. The mortgage is a sugar having intermediate functional properties of known starch and starch syrup. About 20, starch is partially hydrolyzed, purified and concentrated by enzymes. Mortgage is a well-known food material widely used in the food processing field because of its excellent formation and resistance to browning. It is used in coffee primer, food extender and so on. In addition, for example, strawberries contain a large amount of glucose, including low sugar or fructose, and malic acid, citric acid, tartaric acid, and the like provide a sweet and sour taste of strawberries.
본 발명 택사(Alismatis Rhizoma)는 1998년 전남 순천에서 수확한 것을 구입하여 사용하였다. 항균 시험용으로 사용한 균주Bacillus subtilis,Pseudomonas aeruginosa,Escherichia coli,Salmonella typhimurium,Escherichia coliO-157 및Vibrio parahaemolyticus는 한국 종균협회에서 분양 받아 사용하였다. 각종 미생물의 배양에 사용된 배지는 영양 배지(nutrient broth, agar)를 사용하였으며,Vibrio parahaemoliticus는 3% NaCl이 첨가된 배지를 사용하였다. Alismatis Rhizoma of the present invention purchased and used harvested in Suncheon, Jeonnam in 1998. The strains Bacillus subtilis , Pseudomonas aeruginosa , Escherichia coli , Salmonella typhimurium , Escherichia coli O-157 and Vibrio parahaemolyticus were used for antimicrobial testing. Nutrient broth (agar) was used for the culture of various microorganisms, and 3% NaCl was added for Vibrio parahaemoliticus .
택사의 면역활성 측정을 조사하기 위해 사용한 생쥐(BALB/c, C57BL/6)는, 대한실험동물센터(충북 음성군)에서 구입한 후 생후 8∼12주된 암컷을 사용하였으며, 실험 전까지 고형사료와 1차 증류수를 공급하면서 사육하였다. RPMI 1640배지, 안티바이오틱 안티마이코틱은 Gibco BRL(Grand Island, NY, USA)제품을 사용하였으며, FCS(fertal calf serum)은 PAA제품을 사용하였다. LPS와 2-ME(2-mercaptoehtanMice (BALB / c, C57BL / 6) used to investigate the immune activity of taxa were purchased from the Korea Experimental Animal Center (negative group Chungbuk), and 8-12 weeks old females were used. It was bred while supplying tea distilled water. RPMI 1640 medium, antibiotic antimicrobial was used Gibco BRL (Grand Island, NY, USA) products, FCS (fertal calf serum) was used PAA products. LPS and 2-ME (2-mercaptoehtan
ol), NaHCO3, N-1-나프틸-에틸렌-디아민(N-1-naphthyl-ethylen-diamine)과 썰파닐아마이드(Sufanilamide)는 Sigma사 제품을 사용하였다. 또한 세포독성 측정(Cytotoxicity assay)에 사용된 시약(Cyto Tox 96Non-radioactive Cytotoxicity Assay)과 세포증식 측정에 사용된 시약(Cell titer96Aqueous One solution cell proliferation Assay)은 Promega사 제품을 사용하였고, 사이토카인(cytokine)측정에 필요한 항체는 Pharmingen사의 제품을 사용하였다. B 세포 분리에 사용된 Sephadex G-10도 Pharmingen사의 제품을 사용하였다. 세포배양을 위한 세포주로는 생쥐 단핵/대식세포 계열의 세포주인 RAW264.7을 한국세포주은행(서울대학교 의과대학 암연구소)에서 구입하였다. 상기 세포배양을 위한 배지는 RPMI 1640배지에 NaHCO32g/L와 페니실린(penicillin) 100unit/ml, 스트렙토마이신 100mg/ml를 첨가하여 사용하였다.ol), NaHCO 3, N-1-naphthyl-ethylen-diamine and sulfanamide were used by Sigma. In addition, the reagents used in the cytotoxicity assay (Cyto Tox 96). Non-radioactive Cytotoxicity Assay and Reagents Used to Measure Cell Proliferation (Cell titer96) Aqueous One Solution Cell Proliferation Assay was used for Promega, and the antibodies required for cytokine measurement were used for Pharmingen. Sephadex G-10 used for B cell separation was also used by Pharmingen. As a cell line for cell culture, RAW264.7, a mouse mononuclear / macrophage cell line, was purchased from Korea Cell Line Bank (Seoul National University College of Medicine). Medium for the cell culture was used by adding NaHCO 3 2g / L, penicillin 100unit / ml, streptomycin 100mg / ml to RPMI 1640 medium.
항균활성 및 항산화능을 측정하기 위하여 사용한 택사(Alismatis Rhizoma) 추출물은 메탄올, 에탄올 및 물과 같은 용매를 사용하여 택사 100g당 1500ml의 비율로 용매를 첨가하고 환류냉각기를 이용하여 메탄올과 에탄올은 80℃, 물은 100℃에서 2시간 추출한후 택사 g 당 0.5ml가 되도록 농축하여 제조하였다. Alismatis Rhizoma extract used to measure antimicrobial activity and antioxidant activity was added at a rate of 1500 ml per 100 g of taxa using solvents such as methanol, ethanol and water, and methanol and ethanol at 80 ° C using a reflux condenser. , Water was prepared by extracting at 100 ℃ for 2 hours and concentrated to 0.5ml per g of taxi.
본 발명의 택사음료 제조에 부재료로 사용한 사과농축액(SP-6411, Bx 50)은 명신화성에서 제조된 것이며, 산미제로 사용한 구연산과 비타민 C는 홍성약품에서 제조된 것을 구입하여 사용하였다. 감미제로서 사용된 액상과당(고과당)은 두산제품이며 저당(저당70)은 삼양제넥스사에서 제조된 것이고 향료(ruitmix FLA B-8718)는 한불에서 제조된 것을 구입하여 사용하였다. 택사추출물과 생약추출물 및 부재료의 배합성분 및 비율은 시제품을 제조한 뒤 관능평가를 실시하여 최적 배율을 선정하였으며 택사추출물의 경우 2.0∼3.0g/100ml, 대추추출물 1.0∼2.0g/100ml, 구기자추출물 0.1∼1.0g/100ml 및 오미자추출물 0.1∼0.5g/ml등의 생약추출물, 부원료인 사과과즙 1.0∼2.0g/100ml, 구연산 0.01∼0.1g/100ml, 비타민 C 0.01∼0.05g/100ml, 액상과당 10∼15g/100ml, 저당 1.0∼5.0g/100ml 및 향료 0.05∼0.15g/100ml를 첨가하여 제조하였다.Apple concentrate (SP-6411, Bx 50) used as an ingredient in the preparation of the taxi beverage of the present invention was prepared by Myung Shin Hwaseong, and citric acid and vitamin C used as an acidulant were purchased from Hongsung Pharmaceuticals. The liquid fructose (high fructose) used as a sweetener is Doosan's product and the mortgage (70) is manufactured by Samyang Genex and the fragrance (ruitmix FLA B-8718) was purchased from Hanbul. The formulation and ratio of the extracts of the extract, the herbal extract, and the subsidiary ingredient were selected by the sensory evaluation after the preparation of the prototype, and the optimal magnification was selected. Herbal extracts such as 0.1-1.0g / 100ml and Schisandra chinensis extract 0.1-0.5g / ml, apple juice 1.0% -2.0g / 100ml, citric acid 0.01-0.1g / 100ml, vitamin C 0.01-0.05g / 100ml, liquid fructose 10-15 g / 100ml, mortgage 1.0-5.0g / 100ml, and the fragrance | flavor 0.05-0.15g / 100ml were added and prepared.
본 발명 택사건강음료는 택사의 고유한 맛과 신맛, 과일 향취미가 조화를 이루고 있으며 갈색음료의 형태로 청·장년층의 일반 남녀 누구나 수시 음용이 가능하다. 본 발명 택사건강음료의 pH는 3∼4이며 바람직하게는 3.58이고 브릭스(brix)가 12∼13。Bx로 바람직하게는 12.2。Bx인 특징이 있다. 또한 본 발명 택사건강음료는 4℃, 실온, 37℃에서 5개월이 경과하여도 소량의 침전이 생성되나 다른 품질 특성은 안정한 특징이 있다.In the present invention, the health of the taxi is in harmony with the unique taste and sourness of the taxi, and the fruit flavor is in the form of a brown beverage. The present invention is characterized by having a pH of 3-4, preferably 3.58, and brix of 12-13 ° Bx, preferably 12.2 ° Bx. In addition, the present invention is a small amount of precipitate is produced even after 5 months at 4 ℃, room temperature, 37 ℃ in the tax health beverage is another quality characteristic is stable.
본 발명 택사건강음료의 바람직한 제조방법은 도 1에 도시하였다.Preferred method of manufacturing the present taxi health beverage is shown in FIG.
이하, 본 발명의 구체적인 방법을 실시예를 들어 상세히 설명하고자 하지만,본 발명의 권리범위는 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the specific method of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited only to these Examples.
실험예 1: 택사 추출물의 항균효과 조사Experimental Example 1: Investigation of antimicrobial effect of taxa extract
택사 추출물의 항균효과를 조사하기 위하여 택사 추출물을 사용하여 항균력, 미생물 생육도에 미치는 영향, 미생물의 형태변화에 미치는 영향을 조사하였다.In order to investigate the antimicrobial effect of taxa extracts, the effects of antimicrobial activity, microbial growth, and microbial morphology were investigated.
항균력의 측정은 Farag의 방법을 변형하였다. 즉, agar 1.5%가 함유되어 있는 생육배지를 페트리 디쉬(petri dish)의 밑면에 얇게 펴고 그위에 다시 0.6%의 agar가 함유된 생육배지를 부어 2중의 평판 배지를 만든 후 각 균주를 평판배지에 도말하였다. 상기 균주가 도말된 평판배지에 택사추출물을 일정량 가한 직경 0.8cm의 여지 디스크(disc)를 올려놓고 36℃에서 24시간 배양한 뒤, 생성되는 생육저해환을 측정하여 항균력을 조사하였다.The measurement of antimicrobial activity modified Farag's method. That is, the growth medium containing 1.5% of agar is thinly spread on the bottom of a petri dish, and the growth medium containing 0.6% of agar is poured on it to make a double flat medium, and then each strain is placed on the flat medium. Smeared. The strain was placed on a plate medium coated with a certain amount of the tackifier extract 0.8cm in diameter filter disk (disc) and incubated for 24 hours at 36 ℃, the resulting growth inhibition was measured to investigate the antibacterial activity.
미생물의 생육도 측정은 액체배지 희석법을 사용하였다. 시험관에 5ml의 생육배지를 넣고 대수기 중기까지 배양된 균체 배양액 1%를 접종한 후 택사 추출물 함량을 배지 5ml당 30∼200㎕가 되도록 첨가하고 각 균주의 최적 온도에서 배양하면서 경시적으로 미생물의 생육정도를 분광광도계(spectrophotometer)를 사용하여 660nm에서 흡광도를 측정하였다.Microbial growth was measured using the liquid medium dilution method. Inoculate 5 ml of growth medium into the test tube and inoculate 1% of the cell culture cultured up to the middle of the logarithmic season, and then add tac extract extract to 30 to 200 µl per 5 ml of medium and incubate at optimum temperature of each strain. The extent of growth was measured by absorbance at 660nm using a spectrophotometer.
택사(Alismatis Rhizoma) 추출물에 의한 미생물의 형태변화 조사는 식품부패 미생물에 택사 추출물을 처리한 후 전자현미경으로 그 형태 변화를 관찰하였다. 부패미생물로Salmonella typhimurium을 배지에 48시간 배양한 다음 배양 균주 일부에 택사 추출물을 배지 ml당 100㎕로 첨가하고 3시간 방치한 뒤 이를 원심분리하여 균체를 분리한 후 0.05M 인산 완충액(phosphate buffer)으로 희석하고 0.45㎕ membrane filter에 균체를 고정하였다. 이를 5% 글루타알데하이드(glutaaldehyde) 용액에 하룻밤 담구어 멸균수로 세척한 뒤 30∼100%의 에탄올에 차례로 담구어 탈수하고, 이소아밀아세테이트(isoamylacetate)에 약 30분간 담구어 건조시킨 후 전자현미경 촬영시료를 조제하여 관찰하였다.The morphological changes of microorganisms by Alixmatis Rhizoma extracts were treated with food extract microorganisms and their morphological changes were observed by electron microscopy. Incubate Salmonella typhimurium as a decay microorganism in a culture medium for 48 hours, add 100 microliters of taxa extract per ml of culture strain to the culture strain, leave for 3 hours, and centrifuge to isolate the cells. 0.05M phosphate buffer The cells were diluted with and fixed to 0.45 μl membrane filter. Soak overnight in 5% glutaaldehyde (glutaaldehyde) solution, wash with sterile water, and then immerse in 30 ~ 100% ethanol one by one in order to dehydrate, immerse in isoamylacetate for about 30 minutes to dry and electron microscope The photographing sample was prepared and observed.
실험결과, 택사 추출물의 항균 활성은 도 2와 표1에 나타낸 바와 같이, 물추출물이 메탄올 및 에탄올 추출물보다 항균활성이 강하게 나타났다. 또한Escherichia coliO-157균주를 제외한 모든 시험균주에 대하여 항균활성이 강하게 나타났으며 각 시험균주에 대한 택사 추출물의 투명환(clear zone)은Vibrio parahaemolyticus, Bacillus subtilis, Salmonella typhimurium, Pseudomonas aeruginosa 및 Escherichia coli에 대하여 각각 18.0, 16.0, 16.0, 13.0, 11.5mm였으며 특히,Vibrio parahaemolyticus균주에 대해서 항균활성이 가장 강하게 나타났다.Experimental results, as shown in Figure 2 and Table 1, the antimicrobial activity of the taxa extract, water extract showed stronger antibacterial activity than methanol and ethanol extract. Also had antimicrobial activity appeared strongly to all tested strains except for Escherichia coli O-157 strain clear zone (clear zone) of Alismataceae extract of each test strain Vibrio parahaemolyticus, Bacillus subtilis, Salmonella typhimurium, Pseudomonas aeruginosa and Escherichia coli Were 18.0, 16.0, 16.0, 13.0, and 11.5mm, respectively. In particular, the antimicrobial activity of Vibrio parahaemolyticus was the strongest.
택사(Alismatis Rhizoma) 추출물이 미생물의 증식에 미치는 영향을 조사한 결과, 도 3a∼3e에 나타낸바와 같이 택사추출물을 배지 5ml당 30㎕만 첨가하여도 균의 성장이 억제되었으며 150㎕ 첨가시는 거의 모든 균에서 대조구에 비하여 50% 이상 균의 성장이 억제되었으며, 200㎕ 첨가시는 균의 성장이 거의 억제되었다.As a result of investigating the effect of Alismatis Rhizoma extract on the growth of microorganisms, as shown in Figs. 3a to 3e, the growth of the bacteria was inhibited even by adding 30 μl of the Taxa extract per 5 ml of the medium. The growth of the bacteria was inhibited by more than 50% compared to the control, and the growth of the bacteria was almost inhibited when 200μl addition.
택사 추출물 처리에 따른 미생물의 형태 변화를 조사한 결과, 도 3에 나타낸 바와 같이Salmonerlla typhimurium에 택사 물추출물을 처리한 후 대조구와 비교시 균체의 표층구조가 허물어지는 심한 형태적 변화를 나타내었다. 서 등(서권일,이상원, 양기호 :한국농산물저장유통학회(1999), 6(1))은E.coliO-157에 산수유 물추출물을 처리한 후 전자현미경으로 관찰한 결과 대조구와 비교하여 산수유 물추출물을 처리한 균체에서 세포막 기능이 파괴되어 세포내용물이 균체 외부로 유출되어 균체의 생육이 억제되는 현상을 나타내었다고 보고하였고, 서 등은 대장균에 겨자 물추출물을 처리하였을 때 균체 표면이 수축되고 표층구조가 심하게 허물어졌다고 보고하였는데, 본 결과의 이와 같은 현상들도 상기의 연구보고와 비교하여 볼 때 택사 물추출물에 의한 미생물의 세포벽 및 세포막의 기능이 파괴되어 용균이나 균체성분의 노출로 인한 결과라고 생각된다.As a result of investigating the morphological changes of the microorganisms according to the extract of the taxa extract, as shown in FIG. 3, after treating the taxa water extract with Salmonerlla typhimurium , the surface structure of the cells was severely compared with the control group. Seo et al. (Seo Kwon Il, Sang Won Lee, Ki Ho Ho: Korean Agricultural Products Storage and Distribution Association (1999), 6 (1)), treated with E. coli O-157 extracts of cornus water, were observed by electron microscopy. It was reported that the cell membrane function was disrupted in the cells treated with the extract and cell contents leaked to the outside of the cells, thereby inhibiting the growth of the cells. It was reported that the structure was severely collapsed.These phenomena are also the result of the exposure of lysates or cell components due to the destruction of the cell wall and cell membrane of microorganisms by taxi water extract. I think.
실험예 2: 택사 추출물의 항산화 효과 조사Experimental Example 2: Investigation of Antioxidant Effect of Taxa Extract
택사 추출물(Alismatis Rhizoma)의 리놀레산(linoleic acid)에 대한in vitro항산화 및 간 지질과산화 억제 기능에 대하여 조사하였다. 택사 추출물의 항산화 효과 측정을 위하여 삼각플라스크에 리놀레산(linoleic acid) 1g, 에탄올(ethanol) 10ml 및 소정의 택사 추출물을 첨가한 후 0.2M 인산완충용액(phosphate buffer) 25ml를 가하여 37℃에서 일정기간 저장한 다음 반응용액을 분액깔대기에 옮겨 클로로포름(chloroform) 25ml를 가하여 2∼3회 반복 추출하였다. 상기 클로로포름(chloroform) 추출액에 아세트산(acetic acid) 25ml와포화 KI용액 1ml를 가하여 암소에서 5분간 방치한 다음 증류수 50ml를 가하여 1/100 N Na2S2O3용액으로 적정하였다. 택사추출물은 각각 메탄올, 에탄올, 물추출물을 첨가하였고, BHT 0.1%를 첨가하여 50℃에서 7일간 저장하면서 과산화물가를 측정하였다.The in vitro antioxidant and hepatic lipid peroxidation inhibitory effects on linoleic acid of Alismatis Rhizoma were investigated. In order to measure the antioxidant effect of taxa extract, 1 g of linoleic acid, 10 ml of ethanol, and a predetermined taxa extract were added to a Erlenmeyer flask, and 25 ml of 0.2 M phosphate buffer was added and stored at 37 ° C. for a period of time. Then, the reaction solution was transferred to a separatory funnel, and 25 ml of chloroform was added thereto, followed by extraction two to three times. 25 ml of acetic acid and 1 ml of saturated KI solution were added to the chloroform extract, which was allowed to stand in the dark for 5 minutes, and then 50 ml of distilled water was added thereto and titrated with a 1/100 N Na 2 S 2 O 3 solution. Taxi extract was added methanol, ethanol, and water extract, respectively, and BHT 0.1% was added and stored at 50 ° C. for 7 days to measure peroxide value.
택사 추출물의 지질과산화 억제효과는 흰쥐의 간 균질액(liver homogenate)를 사용하여in vitro로 조사하였다. 흰쥐의 간을 적출하여 인산완충용액(phospha-Lipid peroxidation inhibitory effect of Taxa extract was investigated in vitro using liver homogenate in rats. Phosphate buffer solution (phospha-
te buffer, pH 7.4)로 균질화한 다음 균질액에 과산화수소(H2O2) 1M과 50mM의 황산철(FeSO4) 및 택사 추출물 0.05ml를 가하여 42℃에서 72시간 동안 저장한 후 생성된 TBARS(thiobarbituric acid reactive substances)함량을 측정하였다.After homogenization with te buffer, pH 7.4), 1M of hydrogen peroxide (H 2 O 2 ), 50 mM iron sulfate (FeSO 4 ), and 0.05 ml of taxa extract were added to the homogenate, and stored at 42 ° C. for 72 hours. thiobarbituric acid reactive substances) was measured.
실험결과, 도 5에 나타낸 바와 같이 택사 메탄올 추출물, 에탄올 추출물 및 물추출물 100㎕ 첨가시 대조구에 비하여 과산화가가 모두 낮게 나타났으며, 물추출물의 과산화물가는 메탄올 및 에탄올 추출물보다 작았으나, 0.1% BHT 첨가시 보다는 조금 높게 나타났다. 또한 택사 물추출물을 50, 100, 150 및 200㎕의 농도로 첨가한 후 과산화물가를 측정한 결과 도 6에 나타낸 바와 같이 모두 대조구에 비하여 매우 낮게 나타났으며, 150㎕ 첨가시는 5일 저장시까지 과산화물이 거의 생성되지 않았는데 이는 0.1% BHT 100㎕를 첨가한 경우와 비슷한 정도의 효과였다. 권 등(권오근, 손진창, 김상철, 정신교, 박승우 :한국농산물저장유통학회(1998), 5(281))은 목단피 메탄올 추출물의 에칠아세테이트 분획의 리놀레산(linoleic acid)에 대한 항산화 효과가 87.3%이었고, 비교구인 BHT는 96.2%로 나타났다고 보고하였고,서 등(서권일, 이상원, 양기호 :한국농산물저장유통학회(1999), 6(1))은 리놀레산(linoleic acid)에 대하여 산수유 물추출물을 10, 30 및 50㎕ 첨가하고 50℃에서 7일간 저장한 후 과산화물가를 측정한 결과 대조구의 187meq/kg에 비하여 42, 30 및 25meq/kg으로 나타나 상당한 항산화 효과가 있는 것으로 보고하였는데, 본 실험결과 택사 물추출물을 50㎕만 첨가하여도 상당한 항산화 효과가 있는 것으로 나타났다.As a result, as shown in FIG. 5, when the methanol extract, ethanol extract, and water extract 100 μl were added, the peroxide value was lower than that of the control, and the peroxide value of the water extract was smaller than that of the methanol and ethanol extracts, but was 0.1% BHT. A little higher than when added. In addition, as a result of measuring the peroxide value after adding the water extracts of the taxi water at the concentrations of 50, 100, 150 and 200 μl, as shown in FIG. 6, all of them were very low compared to the control, and when 150 μl was added, the peroxide was stored until 5 days storage. This was hardly produced, which was about the same as adding 100 μl of 0.1% BHT. Kwon et al. (Kwon Oh-Geun, Son Jin-Chang, Sang-Chul Kim, Sang-Cheol Kim, Pyo-Sang, Park, Seung-Woo: The Korean Society for Agricultural Products and Storage (1998), 5 (281)) showed that the antioxidant effect of the ethyl acetate fraction of linoleus methanol extract on linoleic acid was 87.3%. BHT of the comparison group was reported to be 96.2%, and Seo et al. (Seo, Kwon-Il, Sang-Won Lee, and Ki-Ho Yang: Korean Agricultural Products Storage and Distribution Association (1999), 6 (1)) showed that the extracts of linusic acid were 10, 30 and After adding 50 μl and storing at 50 ° C. for 7 days, the peroxide value was measured to be 42, 30 and 25 meq / kg compared to 187 meq / kg of the control, which showed a significant antioxidant effect. Addition of only μl showed significant antioxidant effect.
흰쥐의 간 지질에 대한 TBA가는 도 7에 나타낸 바와같이 택사 물추출물울 첨가하지 않은 대조구에서 3597μmol malondialdehyde(MDA)/g liver이었고, 택사 물추출물을 첨가한 시험구들의 TBA가는 1443 μmol MDA/g liver로서 모두 대조구에 비하여 낮게 나타나 항산화 효과가 있었다.The TBA value of liver lipids in rats was 3597 μmol malondialdehyde (MDA) / g liver in the control group without the addition of tax water extract as shown in FIG. 7, and the TBA value of the test groups to which the water extract was added was 1443 μmol MDA / g liver. All showed lower anti-oxidant effect than the control.
실험예 3: 택사 추출물의 면역활성 측정Experimental Example 3: Determination of Immune Activity of Taxa Extract
택사(Alismatis Rhizoma) 추출물의 면역세포 증식효과, 대식세포주의 일산화질소 생산에 미치는 영향, 동종항원에 대한 증식반응, 동종항원에 의한 T세포 사이토카인(cytokine) 분비량의 억제, 동종항원에 대한 T세포의 살세포 작용 억제효과 등을 조사하였다. 생쥐의 비장세포 분리를 위하여 생쥐(BALB/c)를 경추탈골로 희생시킨 후, 알콜로 소독하여 해부대에 올려놓고 오른쪽 옆구리쪽을 절개하여 비장을 떼어 내었다. 상기 비장을 핀셋을 이용하여 단일세포(single cell)로 만들고 세척용 배지로 3회 세척후 적당량의 10% FCS-RPMI 1640 배지에 희석하여 사용한다. 상기 분리된 비장세포를 10ml의 10% FCS-RPMI 1640에 희석한 후 40㎕ anti-Thy1.2ascites를 넣고 4℃에서 60분간 배양하였다. 그 후에 4℃, 1200rpm에서 6분간 원심침전하여 5ml의 FCS-RPMI 1640에 희석하고 250㎕ rabbit complement를 첨가하여 37℃ 수욕에서 45분간 배양하였다. 그 다음 10ml 세척용 배지로 4℃, 1200 rpm에서 6분간 원심침전을 두 번 반복하고 10% FCS-RPMI 1640 배지 500㎕에 희석하여 세파독스 G-10(Sephadox G-10) 컬럼을 통과시켜서 B세포만을 순수분리 하였다. T세포의 분리는 상기 분리된 비장세포를 10% FCS-RPMI 1640 1ml에 희석하여 Nylon wool 컬럼에 넣고 37℃, 5% CO2배양기에 60분간 배양하였다. 배양후 나일론 울(Nylon wool) 컬럼을 37℃로 미리 데워진 배지로 세척하여 비부착성인 T세포만을 순수 분리하여 alloreative T세포로 사용하였다.Effects of Alismatis Rhizoma Extract on the Proliferation of Immune Cells, Effects of Macrophage Cells on Nitric Oxide Production, Proliferative Response to Homologous Antigens, Inhibition of T Cell Cytokine Secretion by Homologous Antigens, and T Cells Against Homogenous Antigens The inhibitory effect of killer cells was investigated. To separate the splenocytes of the mice, the mice (BALB / c) were sacrificed with cervical distal bone, sterilized with alcohol, placed on the dissection, and the spleen was removed by dissecting the right flank. The spleen is made into single cells using tweezers, washed three times with washing medium, and diluted in an appropriate amount of 10% FCS-RPMI 1640 medium. The isolated splenocytes were diluted in 10 ml of 10% FCS-RPMI 1640, and 40 µl anti-Thy1.2 ascites were added thereto and incubated at 4 ° C. for 60 minutes. Thereafter, the mixture was centrifuged at 4 ° C and 1200rpm for 6 minutes, diluted in 5ml of FCS-RPMI 1640, and incubated for 45 minutes in a 37 ° C water bath by adding 250µl rabbit complement. Then, centrifugation was repeated twice for 6 minutes at 4 ° C. and 1200 rpm with 10 ml washing medium, diluted in 500 μl of 10% FCS-RPMI 1640 medium, and passed through a Sephadox G-10 column. Only cells were purified. Separation of T cells was diluted in 1 ml of 10% FCS-RPMI 1640 and the splenocytes were separated into nylon wool column and incubated for 60 minutes in 37 ℃, 5% CO 2 incubator. After incubation, the nylon wool column was washed with media preheated to 37 ° C., and only non-adherent T cells were purified and used as alloreative T cells.
비장세포, 순수 분리한 B세포, 또는 순수 분리한 T세포에 allogenic 비장세포(C57BL/6)을 96 well plate에 넣고 여기에 택사 추출물을 1, 10, 100, 1000㎍/ml농도로 넣어 배양한 다음 2일, 3일 4일째에 각 세포의 증식정도를 측정하였다. 측정은 Cell titer96Aqueous One Solution Cell proliferation Assay(promega)를 사용하여 2일, 3일, 4일째 각각 배양된 배양액 100㎕에 세포역가측정용 시약(Cell titer) 15㎕씩 첨가하고 4∼8시간 동안 배양한 다음 490nm에서 O.D값을 측정하였다.Splenocytes, purely isolated B cells, or purely isolated T cells were cultured in 96 well plates with allogenic splenocytes (C57BL / 6) in 1, 10, 100, 1000 ㎍ / ml concentrations. Next, the proliferation of each cell was measured on day 2 and day 3 and day 4. Measure the cell titer96 15 μl of cell titer was added to 100 μl of the culture solution on day 2, 3, and 4 using Aqueous One Solution Cell proliferation Assay (promega), followed by incubation for 4 to 8 hours, followed by 490 nm. OD value was measured at.
택사 추출물이 대식세포주의 일산화질소 생산에 미치는 효과를 알아보기 위하여 택사 추출물을 1, 10, 100, 1000㎍/㎖의 농도로 단독 처리하거나 또는 LPS, IFN-γ를 같이 첨가하였을 때, 대식세포가 생산하는 일산화질소의 농도를 측정하였다. 안정된 일산화질소(NO) 산화물인 NO2 -(nitrite)는 Griess 반응을 이용하여 측정하였다. 대식세포주(RAW264.7)를 적당한 조건하에서 48시간 배양한 후 배양 상층액을 96well plate에 100㎕씩 넣고 여기에 Greiss시약 (0.1%N-1-naphthyl-ethylendiamine in H2O + 1% sulfanilamide in 5% H3PO4)을 동량 첨가하여 10분간 반응시킨 후, 마이크로플래이트 리더(microplate reader, TitertekMultiscan Plus, Finland)로 570nm에서 흡광도를 측정하였다. 질산염(Nitrate)의 농도는 질산 나트륨(sodium nitrite)을 32μM에서부터 0.25μM까지 2배씩 희석하여 얻은 표준 곡선과 비교하여 계산하였다.To investigate the effects of taxa extract on nitric oxide production in macrophages, macrophages were treated with 1, 10, 100, and 1000 µg / ml concentrations, or when LPS and IFN-γ were added. The concentration of nitric oxide produced was measured. Stable nitrogen monoxide (NO) oxide, NO 2 - (nitrite) was measured using the Griess reaction. Incubate the macrophage line (RAW264.7) under appropriate conditions for 48 hours, add 100 µl of the culture supernatant to a 96well plate, and add Greiss reagent (0.1% N -naphthyl-ethylendiamine in H 2 O + 1% sulfanilamide in After reacting for 10 minutes by adding the same amount of 5% H 3 PO 4 ), the absorbance was measured at 570 nm with a microplate reader (Titertek Multiscan Plus, Finland). The concentration of nitrate was calculated by comparison with a standard curve obtained by diluting sodium nitrite from 32 μM to 0.25 μM in 2-fold.
택사 추출물이 동종항원에 의한 증식반응에 어떠한 효과를 나타내는지 알아보기 위하여, 동종항원을 유도하기 위한 세포수 결정실험을 수행하였다. 표적세포(Target cells)인 MMC를 처리한 생쥐 C57BL/6의 비장세포와 효과세포(Effector cells)로 비장세포에서 분리한 T세포(생쥐 BABL/c의 T세포)를 함께 3일동안 배양하여 최대 증식반응을 나타내는 조건을 확인하였다.In order to investigate the effects of taxa extract on the proliferative response by homologous antigens, cell number determination experiments were performed to induce homologous antigens. Splenocytes of mouse C57BL / 6 treated with MMC, which are target cells, and T cells (T cell of mouse BABL / c), which were isolated from splenocytes with effector cells, were cultured together for 3 days. The conditions showing the proliferative response were confirmed.
동종항원에 의한 T세포의 증식반응이 택사 추출물에 의하여 유의하게 억제된 원인을 알아보기 위하여, 동종항원에 반응하는 T세포가 분비하는 사이토카인(cytokine)의 생산량을 측정하였다. T세포가 반응할 때 분비하는 사이토카인(cytokine)의 양은 비장세포와 택사를 같이 배양한 상층액을 24시간 후에 회수하여 상층액에 포함된 IL-2, IL-4, IFN-γ,IL-10의 양을 ELISA(enzyme linked immounso-In order to determine the cause of the proliferation of T cells caused by allogeneic antigens significantly inhibited by the taxa extract, the amount of cytokines produced by T cells in response to allogeneic antigens was measured. The amount of cytokines secreted when T cells reacted was recovered after 24 hours of supernatant cultured with splenocytes and taxa, and IL-2, IL-4, IFN-γ, IL- contained in the supernatant. The amount of 10 ELISA (enzyme linked immounso-
rbent assay)kit로 측정하였다. 이때 사이토카인(cytokine) 농도의 측정 한계치는 10pg/ml이었다.It was measured by an rbent assay kit. At this time, the limit of measurement of cytokine concentration was 10 pg / ml.
비장세포 분리방법을 이용하여 C57BL/c 생쥐로부터 비장세포를 분리하여 마지막에 2ml의 10% FCS-RPMI 배지에 희석하고 200㎕의 마이토마이신 C(mytomycin C) 2mg/ml를 첨가하여 37℃ 수욕(water bath)에 25분간 처리하였다. 그 다음 세척용 배지로 4℃, 1200rpm에서 6분간 원심침전을 다섯번 반복하여 세척한 다음 allogen-Splenocytes were isolated from C57BL / c mice using the splenocyte separation method, diluted in 2ml of 10% FCS-RPMI medium, and 200mg of mytomycin C was added to 2mg / ml. (water bath) was treated for 25 minutes. Then, wash repeatedly with centrifuged sedimentation for 5 minutes at 4 ℃ and 1200rpm for 5 minutes with washing medium.
ic 비장세포 또는 표적세포로 사용하였다.Used as ic splenocytes or target cells.
표적세포(Target cell, allogeneic spleen cells, 1×107, 5×106/well)와 효과세포(Effetor cell,T cells, 1×106/well)의 비율(ratio)을 10:1 또는 5:1로 하여 둥근바닥 96well plate에 최종부피가 100㎕되도록 넣고 4℃, 250g에서 5분간 원심침전 시킨 후 37℃, 5% CO2배양기에 8시간 배양하였다. 단, 배양시간이 8시간이 되기 45분전에 Target maximum과 부피보정 대조구(Volume correcting control)에는 용해완충용액(Lysis Buffer)를 10배 희석하여 첨가하여 세포의 용해도가 최대가 되도록 하였다. 배양 후 4℃, 250g에서 5분간 원심침전 시킨 다음 상층액 50㎕를 떠서 평평한 바닥의 96well plate에 옮기고 여기에 50㎕ 기질혼합 완충용액(substrate mix Buffer)를 첨가하고 실온에서 알루미늄 호일을 덮어 30분간 반응시킨 다음 50㎕ 정지용액(stop soultion)을 넣고 마이크로플래이트 리더(microplate reader)를 이용하여 490nm에서 O.D.를 측정하고 상층액내에 있는 락테이트 디하이드로게나아제(lactate dehydrogenase, LDH)의 양을 측정하여 살세포작용 정도를 나타내었다. 살세포작용 정도는 하기의 식을 이용하여 산출하였다.The ratio of target cells (allogeneic spleen cells, 1 × 10 7 , 5 × 10 6 / well) and effector cells (Effetor cell, T cells, 1 × 10 6 / well) is 10: 1 or 5 : into a final volume of 96well round bottom plate 1 so as to 100㎕ were incubated 8 hours for 4 ℃, then centrifuged 5 minutes in the precipitation 250g 37 ℃, 5% CO 2 incubator. However, 45 minutes before the incubation time was 8 hours, the target maximum and volume correcting control (Lysis Buffer) was diluted 10-fold and added to the cell solubility to the maximum. After incubation, centrifuged for 5 minutes at 250 g at 4 ° C. Then, 50 µl of the supernatant was transferred to a 96-well plate on a flat bottom, and 50 µl substrate mix buffer was added thereto, and the aluminum foil was covered at room temperature for 30 minutes. After the reaction, 50 μl stop soultion was added and the OD was measured at 490 nm using a microplate reader. The amount of lactate dehydrogenase (LDH) in the supernatant was measured. The degree of killer cell activity was shown. The degree of killer cell activity was calculated using the following equation.
생쥐의 비장세포에 택사 추출물을 농도별로 처리하여 세포의 증식정도를 측정한 결과 도 8a에 나타낸 바와 같이 무처리 대조군에 비해 택사 추출물을 처리한 실험군의 비장세포 증식정도가 농도 의존적으로 증가함을 알 수 있었다. 비장세포에 포함되어 있는 B세포만을 분리하여 택사의 B세포증식 유도효과를 측정한 결과, 도 8b에 나타낸바와 같이 비장세포에서와 마찬가지로 농도 의존적으로 증식을 증가시켰으며 특히 1000㎍/㎕의 농도에서는 월등한 상승효과가 있음을 알 수 있었다.As a result of measuring the proliferation of cells by the concentration of taxa extract in the spleen cells of the mouse by concentration, as shown in FIG. 8a, the concentration of the splenocytes in the experimental group treated with the extract was increased in a concentration-dependent manner as shown in FIG. Could. As a result of measuring the induction of B cell proliferation of taxa by separating only B cells contained in splenocytes, as shown in FIG. 8B, proliferation was increased in a concentration-dependent manner as in splenocytes, especially at a concentration of 1000 ㎍ / μl. It was found that there was an excellent synergistic effect.
택사 추출물이 대식세포주의 일산화질소(NO) 생산에 미치는 효과를 조사한 결과, 표 2에 나타낸바와 같이 무처리 대조군과 비교해보면 택사 추출물을 농도별로 단독 처리한 실험군과 LPS를 1㎍/㎖을 같이 처리한 실험군에서는 모두 대식세포의 일산화탄소(NO) 생산이 유도되지 않았다. 그러나 1ng/㎖의 IFN-γ를 같이 처리한 실험군에서는 택사 추출물의 농도가 낮을때는 약간 감소하는 경향을 보였지만, 고농도에서 일산화질소(NO)생산이 유의성 있게 증가하였다. 즉, 택사추출물이 1000㎍/㎕같은 고농도에서는 IFN-γ에 의해 유도되는 일산화질소(NO) 생산에 상승적 작용을 하는 것을 알 수 있었다.As a result of investigating the effect of taxa extract on nitric oxide (NO) production of macrophage, as compared to the untreated control group, as shown in Table 2, the experimental group treated with taxa extract alone by concentration and LPS were treated together with LPS. None of the experimental groups induced carbon monoxide (NO) production in macrophages. However, the experimental group treated with 1 ng / ml IFN-γ showed a tendency to decrease slightly at low concentrations of taxa extract, but significantly increased NO production at high concentrations. In other words, it can be seen that the taxa extract has a synergistic effect on the production of nitrogen monoxide (NO) induced by IFN-γ at high concentrations such as 1000 µg / µl.
택사 추출물이 동종항원에 의한 증식반응에 미치는 효과를 조사한 결과, 도 9a에 나타낸 바와 같이 동일한 표적세포의 수(5×105cells/well)일 때 효과세포의 수가 well당 1×106cells이 배양 후 3일째에 최대 증식반응을 나타내었다. 따라서, 동일한 조건에서 0.01, 0.1, 1, 10㎍/㎖의 택사 추출물을 같이 처리하여 배양 후 3일째 증식반응을 측정한 결과, 도 9b에 나타낸 바와 같이 택사 추출물의 농도 의존적으로 동종항원에 대한 증식반응이 억제되었다. 즉, 1㎍/㎖에서 최대 약 50%정도의 증식 억제효과를 나타냈다.As a result of investigating the effect of taxa extract on the proliferative response by homologous antigen, as shown in FIG. 9A, the number of effect cells was 1 × 10 6 cells per well when the same number of target cells (5 × 10 5 cells / well). Maximum proliferative response was seen at 3 days after culture. Therefore, as a result of measuring the proliferative response on day 3 after cultivation by treating 0.01, 0.1, 1, 10 ㎍ / ml taxa extract under the same conditions, as shown in FIG. The reaction was suppressed. In other words, the maximum inhibitory effect of about 50% at 1 ㎍ / ㎖.
T세포가 생산하는 사이토카인(cytokine)의 생산량을 측정한 결과, 표 3에 나타낸 바와 같이 동종항원에 대해 반응하는 T세포는 IL-2, IL-10 및 IFN-γ 등을 생산하였지만, 택사 추출물을 첨가한 실험군에서 IL-2, IFN-γ 및 IL-10의 생산량이 억제됨을 알 수 있었다. 따라서, 택사 추출물은 동종항원에 대해 반응하는 T세포의 사이토카인(cytokine) 생산을 억제함으로써 분열 증식을 저해하는 것으로 생각된다.As a result of measuring the amount of cytokines produced by T cells, T cells responding to homologous antigens produced IL-2, IL-10 and IFN-γ, as shown in Table 3. It was found that the production of IL-2, IFN-γ and IL-10 was suppressed in the experimental group added. Therefore, it is thought that the taxa extract inhibits cleavage proliferation by inhibiting cytokine production of T cells in response to homologous antigens.
택사 추출물이 동종항원에 대한 T세포의 살세포작용에 미치는 영향을 조사한 결과, 도 10에 나타낸바와 같이 동종항원에 대한 T세포의 살세포 작용을 택사 추출물이 저농도인 1㎍/㎖에서 완전히 억제함을 알 수 있었다. 따라서, 택사 추출물은 동종항원에 대한 T세포의 사이토카인(cytokine) 생산량을 억제함으로써 분열증식을 억제하였고, T세포의 동종항원에 대한 살세포 작용도 억제하는 것으로 나타났다.As a result of investigating the effect of taxa extract on the T cell apoptosis on allogeneic antigen, as shown in FIG. 10, the activity of T cells on the homologous antigen was completely inhibited at a low concentration of 1㎍ / ml And it was found. Therefore, the extract of Taeksa inhibited the proliferation by inhibiting the cytokine production of T cells against homologous antigens, and also inhibited the killer cell activity against homologous antigens of T cells.
실시예 1: 택사음료의 제조Example 1 Preparation of Taxa Drink
제 1공정: 택사추출물 및 생약추출물의 제조Step 1: Preparation of Taxa Extracts and Herbal Extracts
택사와 대추, 구기자 및 오미자등의 생약제에 각각 10배의 물을 가수하여 80℃에서 5시간 동안 2회에 거쳐 추출하였다. 상기 추출액을 5∼10℃, 8,000rpm에서 20분간 원심분리한 후 여과하여 상징액을 획득하고 Bx50 정도 되도록 60℃이하로 유지하면서 수분 함량 40%까지 감압 농축하였다. 이때, 농축액의 고형분 수율을 측정한 결과, 표 4에 나타낸 바와 같이 택사의 경우 34.45%로 가장 많았으며, 구기자, 오미자, 대추순이였다.Ten times of water was added to medicinal herbs such as taxa, jujube, wolfberry, and Schisandra chinensis, respectively, and extracted with two times at 80 ° C. for 5 hours. The extract was centrifuged at 5 to 10 ° C. at 8,000 rpm for 20 minutes, filtered to obtain supernatant, and concentrated under reduced pressure to 40% of water while maintaining the temperature at 60 ° C. or less. At this time, as a result of measuring the solids yield of the concentrate, as shown in Table 4, the most number of taxis were 34.45%, followed by wolfberry, Schisandra chinensis, Jujube.
제 2공정: 택사추출물, 생약추출물 및 부재료의 배합Second Step: Blending Taxa Extract, Herbal Extract and Substance
먼저, 제 1공정에서 제조한 택사 추출물의 음용농도를 결정하기 위하여 택사추출물의 농도를 각각 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0%의 농도로 만든 다음, 생약재인 대추 구기자 및 오미자와 부재료인 사과과즙, 산미제, 감미제, 향료등을 적정 농도로 첨가하여 수십회에 걸쳐 관능평가를 실시하여 배합적성, 제조특성, 품질특성 등을 고려하여 최종 시제품의 배합성분과 비율을 표 5에 나타낸 바와 같이 선정하였다. 선정된 최적 배합 비율에 따라 택사추출물, 생약추출물, 부재료 등을 칭량하고 혼합하였다.First, in order to determine the drinking concentration of the taxa extract prepared in the first step, the concentration of the extract of the taxa extract to 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0%, respectively, then the herbal medicine jujube wolfberry and Sensory evaluation was conducted several times several times by adding appropriate amounts of apple juice, acidulant, sweetener, and fragrance, such as Schisandra chinensis and the ingredients, and considering the formulation suitability, manufacturing characteristics, quality characteristics, etc. Selection was made as shown in 5. Taxa extract, herbal extracts, subsidiary materials and the like were weighed and mixed according to the selected optimal blending ratio.
제 3공정: 가향, 정용 및 여과Third process: flavoring, dressing, and filtration
제 2공정에서 제조한 택사추출물, 생약추출물 및 보조제 혼합물에 향료를 0.1g/100ml되도록 가하고 정제수를 첨가하여 정용한 뒤 1㎛의 필터로 막여과(membrane filteration)하였다.Perfume was added to 0.1 g / 100 ml of the taxi extract, the herbal extract and the adjuvant mixture prepared in the second step, and purified by adding purified water, followed by membrane filtration with a 1 μm filter.
제 4공정 : 살균 및 충전4th process: Sterilization and filling
제 3공정에서 제조한 여과액을 93℃에서 15초간 순간 살균한 다음 100ml를 용기에 넣어 충전하였다.The filtrate prepared in the third step was sterilized at 93 ° C. for 15 seconds and then charged into a 100 ml container.
제 5공정 : 살균 및 포장5th Process: Sterilization and Packaging
상기 충전된 시료를 80℃에서 20분간 살균한 다음 포장하여 도11에 나타낸 바와 같이 제품화하였다.The packed sample was sterilized at 80 ° C. for 20 minutes and then packaged to produce a product as shown in FIG. 11.
이상, 상기 실시예를 통하여 설명한 바와 같이 본 발명의 항균활성, 항산화효과 및 면역활성이 뛰어난 택사추출물을 대추, 구기자 및 오미자 등의 생약재추출물과 사과 과즙, 산미제, 감미제 및 향료와 함께 혼합하여 음료로 제조함으로서 기능성이 증진된 택사건강음료를 제조하는 효과가 있으므로 식음료산업과 국민건강증진에 있어서 매우 유용한 발명인 것이다.As described above, the beverages are mixed with medicinal herb extracts, such as jujube, wolfberry and Schisandra chinensis, apple juice, acidulant, sweetener and flavoring agent, which have excellent antimicrobial, antioxidant and immune activities. It is a very useful invention in the food and beverage industry and national health promotion because it has the effect of producing a functional health-enhanced taxi health drink.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0078052A KR100440493B1 (en) | 2000-12-18 | 2000-12-18 | Healthy drink comprising Alismatis Rhizoma extract and process for prepatration therof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0078052A KR100440493B1 (en) | 2000-12-18 | 2000-12-18 | Healthy drink comprising Alismatis Rhizoma extract and process for prepatration therof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020048779A KR20020048779A (en) | 2002-06-24 |
KR100440493B1 true KR100440493B1 (en) | 2004-07-15 |
Family
ID=27682982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0078052A KR100440493B1 (en) | 2000-12-18 | 2000-12-18 | Healthy drink comprising Alismatis Rhizoma extract and process for prepatration therof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100440493B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103504396A (en) * | 2012-06-18 | 2014-01-15 | 贵州神奇集团控股有限公司 | Lipid-lowering beverage and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100949605B1 (en) * | 2008-03-13 | 2010-03-25 | 무주군약초영농조합법인 | Products of Schisandra chinensis Using Extract and Method Thereof |
-
2000
- 2000-12-18 KR KR10-2000-0078052A patent/KR100440493B1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103504396A (en) * | 2012-06-18 | 2014-01-15 | 贵州神奇集团控股有限公司 | Lipid-lowering beverage and preparation method thereof |
CN103504396B (en) * | 2012-06-18 | 2015-06-17 | 贵州神奇集团控股有限公司 | Lipid-lowering beverage and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20020048779A (en) | 2002-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11564952B2 (en) | Water-soluble and water-insoluble propolis products with high antioxidant capacity and their production methods | |
KR102127911B1 (en) | The composition of fermented beverage for immunity enhancement and method for production thereof | |
KR102386296B1 (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
KR101806800B1 (en) | Complex natural preservative comprising scutellaria baicalensis extract and method manufacture the same | |
JP2013520515A (en) | Formulas based on Morinda citrifolia and iridoids | |
Yigit | Antimicrobial and Antioxidant evaluation of fruit extract from Cornus mas L. | |
KR101871247B1 (en) | Functional grain syrup containing prunus mume extract and preparing method thereof | |
Chunhieng et al. | Detailed study of the juice composition of noni (Morinda citrifolia) fruits from Cambodia | |
JP2006265118A (en) | Antibacterial agent and antibacterial composition containing extract of plant of family sapotaceae | |
KR100440493B1 (en) | Healthy drink comprising Alismatis Rhizoma extract and process for prepatration therof | |
KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
KR101004361B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR20170053536A (en) | Beverages for preventing respiratory disease and hyperlipidemia containing Platycodon grandiflorum and its preparing method | |
Heirangkhongjam et al. | Nutritional evaluation of Rhus chinensis Mill.(Heimang) and development of value added products | |
KR20220113327A (en) | A composition comprising an extract of Dendranthema Zawadskii for preventing and treating inflammatory disease | |
KR100392277B1 (en) | Alismatis Rhizoma tea of granule type and process for prepatration therof | |
KR20180106968A (en) | Herb vinegar and manufacturing method thereof | |
KR100392775B1 (en) | Alismatis Rhizoma tea of rosted type and process for prepatration thereof | |
KR20020048778A (en) | Alismatis Rhizoma fermented wine and process for prepatration therof | |
Al-Hamdani et al. | EVALUATION OF INHIBITORY EFFICIENCY OF STEVIA’S EXTRACT IN MICROORGANISMS THAT CAUSE FOOD SPOILAGE. | |
KR101891408B1 (en) | A composition comprising ganoderma lucidum grown on hulled barley extracts having anti-oxidation or anti-inflammation activity | |
KR20170059221A (en) | Antioxidant or anti-aging composition comprising the extract of stem and leaf of Rubus coreanus Miquel | |
Lee et al. | Elicitor-treated extracts of Saururus chinensis inhibit the expression of inducible nitric oxide synthase and cyclooxygenase-2 enzyme expression in raw cells for suppression of inflammation | |
KR20200081943A (en) | Method for producing Aralia continentalis herbal drink | |
KR20050076325A (en) | Health food containing distilled pine-needle extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130805 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140703 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150626 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160518 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 16 |